Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Completed · Phase 4

Conditions studied: Scars

In brief

The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Key facts

Study ID

NCT00450775

Run by

Innovative Medical

People needed

12

Starts

2007-03-01

Expected to finish

2008-03-01

Last updated by the study team

2008-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Female or male patients at least 18 years of age
• Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
• Able and willing to provide informed consent and likely to complete all study visits
• All Fitzpatrick skin types will be evaluated

You may not qualify if…

• Known contraindications to Dermatix or any of its components
• Age of scar is > 4 months
• Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Where it is running

• Dadeland Dermatology — Coral Gables, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.